Until this year, babies across Canada were only given an antibody drug that protects against severe RSV if they were born prematurely or had other significant risk factors.
Although treatments can often seem standard and straightforward, the more we know about the patient, the better our chance of helping them to achieve successful outcomes.
As we witness the advancement of AI, the question arises as to whether empathetic communication can only be mastered by the human clinician – and whom the patient of the future would choose.
